A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies

Fabry disease results from deficient alpha -galactosidase A (alpha -Gal A) activity and the pathologic accumulation of the globotriaosylceramide (GL-3 ) and related glycosphingolipids, primarily in vascular endothelial lysosom es. Treatment is currently palliative, and affected patients generally die in their 40s or 50s. Preclinical studies of recombinant human alpha -Gal A (r-h alpha GalA) infusions in knockout mice demonstrated reduction of GL-3 in tissues and plasma, providing rationale for a phase 1/2 clinical trial. Here, we report a single-center, open-label, dose-ranging study of r-h alph a GalA treatment in 15 patients, each of whom received five infusions at on e of five dose regimens. Intravenously administered r-h alpha GalA was clea red from the circulation in a dose-dependent manner, via both saturable and non-saturable pathways. Rapid and marked reductions in plasma and tissue G L-3 were observed biochemically, histologically, and/or ultrastructurally. Clearance of plasma GL-3 was dose-dependent. In patients with pre- and post treatment biopsies, mean GL-3 content decreased 84% in liver (n = 13), was markedly reduced in kidney in four of five patients, and after five doses w as modestly lowered in the endomyocardium of four of seven patients. GL-3 d eposits were cleared to near normal or were markedly reduced in the vascula r endothelium of liver, skin, heart, and kidney, on the basis of light- and electron-microscopic evaluation. In addition, patients reported less pain, increased ability to sweat, and improved quality-of-life measures. Infusio ns were well tolerated; four patients experienced mild-to-moderate reaction s, suggestive of hypersensitivity, that were managed conservatively. Of 15 patients, 8 (53%) developed IgG antibodies to r-h alpha GalA; however, the antibodies were not neutralizing, as indicated by unchanged pharmacokinetic values for infusions 1 and 5. This study provides the basis for a phase 3 trial of enzyme-replacement therapy for Fabry disease.